Sign in

    Kenny Shannon

    Research Analyst at Jeffries

    Kenny Shannon is a Research Analyst at Jefferies, specializing in biotechnology and healthcare sector research. He has covered companies such as Corbus Pharmaceuticals Holdings, engaging directly with company leadership on earnings calls and demonstrating targeted expertise in pharmaceutical equities. While specific performance metrics and rankings are not broadly published, his active role in analytical coverage is evidenced by contributions to corporate research and participation in major sector events. Shannon began his analyst career at Jefferies, with available records indicating his current tenure at the firm, though details of prior experience and FINRA registrations are not publicly documented.

    Kenny Shannon's questions to Corbus Pharmaceuticals Holdings (CRBP) leadership

    Kenny Shannon's questions to Corbus Pharmaceuticals Holdings (CRBP) leadership • Q3 2020

    Question

    Kenny Shannon from Jeffries, on behalf of Murray Recross, asked about the systemic sclerosis trial, questioning how the post-hoc analysis on patients with over two years of background therapy could be incorporated into a potential FDA label and whether new trials would be required. He also inquired about community feedback on a path forward for the cystic fibrosis program and whether the dermatomyositis trial was shortened due to competitor data or an efficacy read-through from other trials.

    Answer

    Barbara White, Chief Medical Officer and Head of Research, clarified that the recently completed Phase 3 systemic sclerosis study is not adequate for regulatory approval as it missed its primary endpoint, and a new Phase 3 study would be necessary. Similarly, for cystic fibrosis, she noted that failing the primary endpoint likely precludes that trial from being used for approval. Dr. White confirmed the decision to shorten the dermatomyositis trial was driven by the evolving competitive landscape, where competitor trials have shorter durations, rather than any read-through from the SSc or CF studies.

    Ask Fintool Equity Research AI